Osteogenesis imperfecta
Drug research and approvals for osteogenesis imperfecta: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 11 studies of osteogenesis imperfecta are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 12 open orphan designations naming it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
- A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)NCT07557446 · Phase 2 · Angitia Biopharmaceuticals Guangzhou Limited · starts Jul 14, 2026
- An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life…NCT07478224 · Not applicable · University Hospital, Ghent · starts Aug 19, 2025
- REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)NCT07412782 · Not applicable · Meyer Children's Hospital IRCCS · starts Dec 4, 2025
- Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaNCT07366086 · Phase 3 · Amgen · starts Mar 18, 2026
- Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis…NCT07287241 · Not reported · Istituto Ortopedico Rizzoli · starts Jun 10, 2025
- Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)NCT07062588 · Phase 2 · Angitia Incorporated Limited · starts Dec 12, 2025
- Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis ImperfectaNCT05927389 · Not applicable · University Hospital, Toulouse · starts Feb 26, 2024
- Audio-vestibular Evaluation of Children and Young Adults With Osteogenesis ImperfectaNCT05419960 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Dec 22, 2022
- Effects of Bisphosphonates on OI-Related Hearing LossNCT04152551 · Phase 4 · Hospital for Special Surgery, New York · starts Nov 2, 2019
Phase 3 8
- SetrusumabSclerostin inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- RomosozumabSclerostin inhibitor
- Risedronic acidFarnesyl diphosphate synthase inhibitor
- Medronic acid
- SomatropinGrowth hormone receptor agonist
- Pamidronic acidFarnesyl diphosphate synthase inhibitor
Phase 2 1
- ErgocalciferolVitamin D receptor agonist
Phase 1 or earlier 5
- BusulfanDNA inhibitor
- CyclosporineCyclophilin A modulator
- CyclophosphamideDNA inhibitor
- FresolimumabTransforming growth factor beta-1 inhibitor
- SAR-439459
How its trials ended
76 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 36% met their primary endpoint, 7% missed it and 57% stopped early.
- Completed, result not reported3343%
- Ongoing2533%
- Met its primary endpoint57%
- Status unknown45%
- Stopped: sponsor or business decision34%
- Stopped: safety23%
- Stopped: other or unclear23%
- Missed its primary endpoint11%
- Stopped: enrollment or feasibility11%
| Sep 23, 2025 | A phase 2, multi-center, randomized, double-blind, placebo-controlled, doseranging study to evaluate the safety and efficacy of AGA2115 in adults with type i,…AGA2115 | Angitia Incorporated Limited | Ongoing |
| Jun 30, 2023 | A phase 3, open-label, multicenter, randomized study to evaluate the efficacy and safety of romosozumab compared with bisphosphonates in children and…Evenity (romosozumab) | Amgen | Ongoing |
| May 24, 2023 | An open-label, randomized, active-controlled, phase 3 study of setrusumab compared with bisphosphonates in pediatric subjects with osteogenesis imperfecta…Setrusumab | Ultragenyx Pharmaceutical | Closed |
| Mar 4, 2022 | A phase 1b, single ascending dose, randomized, double-blind study to evaluate the safety, tolerability, and activity of SAR439459 in adults with osteogenesis…SAR439459 | Sanofi-Aventis Canada Inc | Ongoing |
| Feb 7, 2022 | A randomized, double-blind, placebo-controlled, phase 2/3 study to assess the efficacy and safety of setrusumab in subjects with osteogenesis imperfecta (OI)Setrusumab (BPS804) | Ultragenyx Pharmaceutical | Ongoing |
| Oct 3, 2018 | "multicenter, single-arm open-label extension study to assess long-term safety and efficacy of current or prior treatment with denosumab in children/young…Prolia® | Amgen | Ongoing |
| Apr 13, 2017 | A phase 2b, multicentre, multinational, placebo-controlled, double-blind, dose-finding study in adult patients with type i, iii or iv osteogenesis imperfecta…BPS804 (setrusumab) | Mereo Biopharma 3 Limited | Ongoing |
| Jul 16, 2014 | Prospective, multicenter, single-arm study to evaluate efficacy, safety and pharmacokinetics of denosumab in children with osteogenis imperfecta protocolDenosumab | Amgen | Closed |
| Sep 21, 2026 | 4-(2-Methylanilidocarbamoyl)-phenylacetyl-L-Citrullyl-L-Glut…Treatment of osteogenesis imperfecta | Zhongshan LaiBo RuiChen BioMedicine Co., Ltd.(RabPharma) | Designated |
| Nov 25, 2025 | N-[(2S)-1-[(3aS,6R,6aR)-6-Ethynyl-3-oxohexahydro-2H-furo[3,2…Treatment of osteogenesis imperfecta | OsteoCat Therapeutics AB | Designated |
| May 29, 2024 | Anti-Siglec-15 monoclonal antibody on a human…Treatment of osteogenesis imperfecta | NextCure, Inc. | Designated |
| Nov 3, 2022 | DNA,…Treatment of Osteogenesis Imperfecta | Aptacure Therapeutics Limited | Designated |
| Oct 20, 2022 | A Humanized Bispecific Antibody Neutralizing Both…Treatment of Osteogenesis imperfecta (OI) | Angitia Biopharmaceuticals Guangzhou Limited | Designated |
| Oct 15, 2022 | Anti-human transforming growth factor beta (TGF-Beta)…Treatment of Osteogenesis Imperfecta | Sanofi Genzyme, A Sanofi Company | Designated |
| May 6, 2022 | Allogenic fetal mesenchymal stem cellsTreatment of Osteogenesis Imperfecta | BOOST Pharma Aps | Designated |
| May 10, 2021 | RomosozumabTreatment of Osteogenesis Imperfecta | Amgen Inc. | Designated |
| Aug 19, 2019 | DNA,…Treatment of Osteogenesis Imperfecta | Aptacure Therapeutics Limited | Designated |
| Feb 29, 2016 | Human monoclonal antibody targeting human sclerostinTreatment of osteogenesis imperfecta. | Ultragenyx Pharmaceutical, Inc. | Designated |
| Nov 9, 2015 | Human allogeneic bone marrow derived osteoblastic cellsTreatment of osteogenesis imperfecta. | Biosenic SA | Designated |
| Mar 31, 2003 | AlendronateTreatment of osteogenesis imperfecta in pediatric patients 4 years of age and older | Merck, Sharpe & Dohme Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA